RxDoctor Payments Data

Jennifer Harrison

Psychiatric/Mental Health · Lincoln, NENPI 1881251189

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 297 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 29.3% of the total. Reporting peaked in 2022 at $1,445 and has fallen 90.1% since, to $143 in 2025.

$4,996in general payments, 2019–2025

Across 297 payments — averaging $16.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alkermes, Inc.$942
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$616
  • Otsuka America Pharmaceutical, Inc.$301
  • Supernus Pharmaceuticals, Inc.$286
  • Neurocrine Biosciences, Inc.$210
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$4,996100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,996 in reported general payments places this provider in the 80th percentile of 255 psychiatric/mental health providers in Nebraska.

See all psychiatric/mental health providers in Nebraska

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl15$22,885
LybalviOlanzapine/Samidorphan Malate11$17,285
Paliperidone ErPaliperidone14$1,864
Buspirone Hcl35$821
Desvenlafaxine Succinate ErDesvenlafaxine Succinate20$766
Duloxetine Hcl20$697
Temazepam14$523
Ziprasidone Hcl11$364
Quetiapine Fumarate16$359
Aripiprazole12$332
Risperidone11$141
Clonazepam14$99
Fluoxetine Hcl13$13

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,462$22,88515 claims
Alkermes, Inc.Lybalvi$942$17,28511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 255 psychiatric/mental health providers in Nebraska.

Other psychiatric/mental health in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →